Traduction de «health protection branch communications division » (Anglais → Français) :

HPB Communications Division [ HPBCD | Health Protection Branch Communications Division ]

Public Health Branch [ Community Health Protection Branch ]

Health Protection Branch Task Force on Food Safety Risk Communication

Community action programme on toxicology for health protection

health Protection questions in intra-Community trade in fresh meat

Witnesses: From Health Canada: Denis Gauthier, Assistant Deputy Minister, Information, Analysis and Connectivity Branch; Jerry Lee, Director, Infostructure Systems Management Division, Information, Analysis and Connectivity Branch; Mimi Breton, Executive Director, Hepatitis C Division, Health Promotion and Programs Branch; Catherine Stewart, Director, Policy Development and Coordination Division, Health Promotion and Programs Br ...[+++]anch; David Fransen, Director general, Population Health Directorate, Health Promotion and Programs Branch; Janet Davies, Director, Strategies and Systems for Health Directorate, Health Promotion and Programs Branch; Joel Weiner, A/Director General, Policy, Planning and Coordination Directorate, Health Protection Branch; Dr. Moe Hussain, A/Director, Branch Planning Bureau, Health Protection Branch; Gérard Séguin, Director, Financial Services, Health Protection Branch; Margaret Hassock, A/Director, Financial Services, Administration Program, Departmental Planning and Financial Administration Corporate Services Branch; Janice L. Pound, Acting Manager, Office of Strategic Planning, Communications and Quality, Therapeutic Products Programme; Paul R. Mayers, Acting Director, Bureau of Microbial Hazards, Food Directorate, Health Protection Branch; Greg Hunter, Director, Information Resource Management Division; Hervé Leblanc, Director, Health Canada.

With reference to the antimalarial drug mefloquine administered to Canadian Forces bound for Somalia in 1992-93 and the legal framework under which it was available for use and administered: (a) was mefloquine a licensed drug when it was administered to Canadian Forces, if not what was its status, and how was it legally available; (b) were the Canadian Forces participating in the Lariam (mefloquine) Safety Monitoring Study during this period; (c) was the mefloquine administered in accordance with the Lariam Safety Monitoring Study and the Food and Drug Act; (d) who was the “principal investigator” responsible for the Lariam Safety Monitoring Study in the Canadian Forces; (e) who was the Canadian Forces physician responsible to the “prin ...[+++]cipal investigator” of the Lariam Safety Monitoring Study; (f) what was the role of Canadian Forces physician, Dr. Martin Tepper, in the Lariam Safety Monitoring Study; (g) who was responsible for the Lariam Safety Monitoring Study at the Department of Health's Health Protection Branch during this period; (h) what was the role and responsibility of the Health Protection Branch under the Lariam Safety Monitoring Study and the Food and Drug Act and its regulations in regard to the use of mefloquine by Canadian Forces personnel; (i) when did the Health Protection Branch become aware that mefloquine was being administered to Canadian Forces personnel bound for Somalia; (j) what responsibility did the Canadian Forces have under the Lariam Safety Monitoring Study and the Food and Drug Act prior to the licensing of mefloquine to inform the manufacturer of its use; (k) what responsibility did the Canadian Forces have under the Lariam Safety Monitoring Study and the Food and Drug Act to the soldiers who were administered the drug; (l) did the Canadian Forces fulfil their responsibility to the manufacturer under the Lariam Safety Monitoring Study and the Food and Drug Act prior to the licensing of mefloquine and if so how did they do ...

Witnesses: From the Health Canada: Robert S. Lafleur, Senior Assistant Deputy Minister, Corporate Services Branch; Orvel Marquardt, Director General, Departmental Planning and Financial Administration, Corporate Services Branch; Scott Broughton, A/Assistant Deputy Minister, Health Policy and Consultation Branch; Michel Léger, Director, Consultation and Collaboration Division ...[+++], Information Analysis and Connectivity Branch; Seamus Hogan, Director of Health Demand and Supply Analysis, Information Analysis and Connectivity Branch; Laurette Birch, Director General, Intergovernmental Affairs; Wendy Watson-Wright, Director-General, Policy and Major Projects Directorate, Health Promotion and Programs Branch; Dann Michols, Director General, Therapeutic Products Programme, Health Protection Branch; Paul Mayers, A/Director, Bureau of Biohazards, Health Protection Branch; Serge Lafond, A/Director of Health Insurance Division, Policy and Consultation Branch.

(23) Since the objectives of the action to be taken, namely to establish restrictions on the use of hazardous substances in electrical and electronic equipment cannot be sufficiently achieved by the Member States and can therefore be better achieved at Community level by reason of the scale of the problem and its implications in respect of other Community legislation on recovery and disposal of waste and areas of common interest, such as human health protection, the Community may adopt measures, in accordance with the principle of sub ...[+++]sidiarity as set out in Article 5 of the Treaty.